Actively Recruiting
Studying Dopamine D2 and D3 Receptor Activity in Adults with Treatment Resistant Depression and Major Depressive Disorder
Led by Unity Health Toronto · Updated on 2026-03-16
45
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are investigating the brain function differences in people with Treatment Resistant Depression TRD compared to those with non-resistant Major Depressive Disorder MDD and healthy individuals. The study focuses on dopamine D2 and D3 receptor activity in specific brain areas to better understand TRDs neurobiology. This research aims to inform future treatment development and improve clinical understanding of TRD. Participants include three groups individuals with TRD, those with non-resistant MDD, and healthy controls with no psychiatric history. All participants will be unmedicated and undergo diagnostic PET and PHNO scans. The study involves three visits, including a screening assessment, MRI scan, and PET scan, with the scan order balanced among participants. During the study, participants will complete clinical interviews and depression rating scales to confirm diagnosis and severity. Researchers will collect demographic and medication history data. The main outcome measured is dopamine receptor binding potential over three years. The study is observational and includes safety monitoring, with all procedures conducted at two nearby medical centers.
CONDITIONS
Brief Title
Characterizing Dopamine Receptor Binding in Treatment Resistant Depression
Research Team
S
Sakina J Rizvi, PhD
A
Ariel Graff-Guerrero, MD, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
